<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149664">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902888</url>
  </required_header>
  <id_info>
    <org_study_id>PAA 12-01</org_study_id>
    <nct_id>NCT01902888</nct_id>
  </id_info>
  <brief_title>Evaluation of GORE® VIABAHN® Endoprosthesis for Popliteal Artery Aneurysm</brief_title>
  <acronym>PAA 12-01</acronym>
  <official_title>Retrospective Evaluation of the GORE® VIABAHN® Endoprosthesis for a Popliteal Artery Aneurysm Indication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, non-randomized, single arm, retrospective study of GORE® VIABAHN®
      Endoprosthesis for the treatment of a Popliteal Artery Aneurysm (PAA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the safety and efficacy of the GORE® VIABAHN®
      Endoprosthesis for the treatment of subjects with Popliteal Artery Aneurysms. The study
      population includes subjects with an asymptomatic aneurysm (≥ 2 cm diameter) of the
      popliteal artery, symptomatic aneurysm (no diameter requirement) of the popliteal artery, or
      presence of mural thrombus (no diameter requirement) of the popliteal artery treated with
      the GORE® VIABAHN® Endoprosthesis between January 1, 2002 and December 31, 2010.  Starting
      with most recently treated within the above date range, patients meeting Inclusion/Exclusion
      will be enrolled, until a minimum of 50 subjects with adequate follow up to determine
      primary endpoints through 12 months will be provided.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    FDA requested amendment to protocol. Waiting for approval of Informed Consent script by
    site(s) prior to resuming retrospective enrollment.
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint: The number of patients that do not have a failure of technical success or loss of primary patency.</measure>
    <time_frame>12 months following initial study procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>A composite of freedom from failure of technical success or loss of primary patency at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Number of Serious Adverse Events (related to initial procedure or the device itself) that occur within 30 days of the initial study procedure.</measure>
    <time_frame>30 days following initial study procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>30 day serious adverse events related to the initial study procedure or the study device.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Popliteal Artery Aneurysm</condition>
  <arm_group>
    <arm_group_label>Popliteal aneurysm</arm_group_label>
    <description>GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® VIABAHN® Endoprosthesis</intervention_name>
    <arm_group_label>Popliteal aneurysm</arm_group_label>
    <other_name>Viabahn</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had popliteam aneurysm and were treated with GORE® VIABAHN® Endoprosthesis
        between January 1, 2002 and  December 31, 2010.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received a GORE® VIABAHN® Endoprosthesis between January 1, 2002 and December 31,
             2010 to treat a popliteal artery aneurysm;

          -  Had an asymptomatic aneurysm (≥ 2 cm diameter) of the popliteal artery, or
             symptomatic aneurysm (no diameter requirement) of the popliteal artery, or the
             presence of mural thrombus (no diameter requirement) of the popliteal artery;

          -  Was 18 years of age or older; and

          -  Had an elective popliteal artery aneurysm procedure.

        Exclusion Criteria:

          -  Bilateral popliteal artery aneurysms with initial treatment on the same day

          -  Had previous surgery for the popliteal artery aneurysm in the study limb
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hector Novoa, BS</last_name>
    <role>Study Director</role>
    <affiliation>W. L. Gore &amp; Associates, Inc (sponsor)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vascular Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>July 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>popliteal artery</keyword>
  <keyword>aneurysm</keyword>
  <keyword>popliteal artery aneurysm</keyword>
  <keyword>asymptomatic aneurysm</keyword>
  <keyword>mural thrombus</keyword>
  <keyword>Viabahn</keyword>
  <keyword>Gore</keyword>
  <keyword>Endoprosthesis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
